MA51616A - Inhibiteurs d'adn-pk - Google Patents
Inhibiteurs d'adn-pkInfo
- Publication number
- MA51616A MA51616A MA051616A MA51616A MA51616A MA 51616 A MA51616 A MA 51616A MA 051616 A MA051616 A MA 051616A MA 51616 A MA51616 A MA 51616A MA 51616 A MA51616 A MA 51616A
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitors
- dna
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862618598P | 2018-01-17 | 2018-01-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA51616A true MA51616A (fr) | 2020-11-25 |
Family
ID=65279732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA051616A MA51616A (fr) | 2018-01-17 | 2019-01-16 | Inhibiteurs d'adn-pk |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210060028A1 (fr) |
EP (1) | EP3740479A1 (fr) |
JP (2) | JP7466448B2 (fr) |
KR (1) | KR20200109358A (fr) |
CN (1) | CN111741955B (fr) |
AU (1) | AU2019209290B2 (fr) |
BR (1) | BR112020014140A2 (fr) |
CA (1) | CA3088788A1 (fr) |
EA (1) | EA202091709A1 (fr) |
IL (1) | IL276082B2 (fr) |
MA (1) | MA51616A (fr) |
WO (1) | WO2019143675A1 (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3478829A1 (fr) | 2016-06-29 | 2019-05-08 | Crispr Therapeutics AG | Matériels et méthodes de traitement de la dystrophie myotonique de type 1 (dm1) et d'autres troubles associés |
MA51619A (fr) * | 2018-01-17 | 2021-04-14 | Vertex Pharma | Inhibiteurs de la protéine kinase dépendante de l'adn |
US20200361877A1 (en) * | 2018-01-17 | 2020-11-19 | Vertex Pharmaceuticals Incorporated | Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency |
SG11202107615TA (en) | 2019-01-18 | 2021-08-30 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
JP2022545921A (ja) | 2019-08-27 | 2022-11-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | 反復dnaに関連する障害の治療のための組成物及び方法 |
CN113549092B (zh) * | 2020-04-23 | 2022-10-18 | 山东轩竹医药科技有限公司 | 三并环类激酶抑制剂 |
US20230183751A1 (en) * | 2020-05-21 | 2023-06-15 | Oxford Genetics Limited | Hdr enhancers |
CN114656486B (zh) * | 2020-12-22 | 2023-09-19 | 江苏恒瑞医药股份有限公司 | 嘌呤酮类化合物、其制备方法及其在医药上的应用 |
WO2022182959A1 (fr) | 2021-02-26 | 2022-09-01 | Vertex Pharmaceuticals Incorporated | Compositions et méthodes pour le traitement de la dystrophie myotonique de type 1 avec crispr/slucas9 |
EP4298222A1 (fr) | 2021-02-26 | 2024-01-03 | Vertex Pharmaceuticals Incorporated | Compositions et méthodes de traitement de la dystrophie myotonique de type 1 avec crispr/sacas9 |
EP4347815A2 (fr) * | 2021-05-24 | 2024-04-10 | New York Genome Center, Inc. | Compositions et méthodes pour augmenter l'efficacité d'une réparation par édition précise |
WO2023018637A1 (fr) | 2021-08-09 | 2023-02-16 | Vertex Pharmaceuticals Incorporated | Édition génique d'éléments régulateurs |
CN115287298A (zh) * | 2021-12-13 | 2022-11-04 | 郑州大学第一附属医院 | 用于精准研究铁代谢相关巨噬细胞的小鼠模型、构建方法及应用 |
WO2023215991A1 (fr) * | 2022-05-11 | 2023-11-16 | adMare Therapeutics Society | Composés inhibiteurs d'adn-pk et leurs utilisations |
WO2024013209A1 (fr) * | 2022-07-13 | 2024-01-18 | Astrazeneca Ab | Inhibiteurs de pcsk9 et leurs procédés d'utilisation |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US789538A (en) | 1904-11-11 | 1905-05-09 | Colin E Ham | Dumb-bell. |
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
US5487994A (en) | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
US5356802A (en) | 1992-04-03 | 1994-10-18 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
WO1995019431A1 (fr) | 1994-01-18 | 1995-07-20 | The Scripps Research Institute | Derives de proteine a doigts zinciques et procedes associes |
US6242568B1 (en) | 1994-01-18 | 2001-06-05 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
JP4285766B2 (ja) | 1994-03-23 | 2009-06-24 | オハイオ ユニバーシティ | 緻密にした核酸および細胞へのデリバリ |
USRE45721E1 (en) | 1994-08-20 | 2015-10-06 | Gendaq, Ltd. | Relating to binding proteins for recognition of DNA |
GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
GB2338237B (en) | 1997-02-18 | 2001-02-28 | Actinova Ltd | In vitro peptide or protein expression library |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
ES2341926T3 (es) | 1998-03-02 | 2010-06-29 | Massachusetts Institute Of Technology | Poliproteinas con dedos de cinc que tienen enlazadores mejorados. |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
US7030215B2 (en) | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
ATE309536T1 (de) | 1999-12-06 | 2005-11-15 | Sangamo Biosciences Inc | Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen |
ATE483970T1 (de) | 2000-02-08 | 2010-10-15 | Sangamo Biosciences Inc | Zellen zur entdeckung von medikamenten |
US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
AU2001263155A1 (en) | 2000-05-16 | 2001-11-26 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
US20050267061A1 (en) | 2004-04-08 | 2005-12-01 | Sangamo Biosciences, Inc. | Methods and compositions for treating neuropathic and neurodegenerative conditions |
US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
AU2002336373A1 (en) | 2001-08-20 | 2003-03-03 | The Scripps Research Institute | Zinc finger binding domains for cnn |
US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
CA2474486C (fr) | 2002-01-23 | 2013-05-14 | The University Of Utah Research Foundation | Mutagenese chromosomique ciblee au moyen de nucleases en doigt a zinc |
US7074596B2 (en) | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
US7361635B2 (en) | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US7253273B2 (en) | 2004-04-08 | 2007-08-07 | Sangamo Biosciences, Inc. | Treatment of neuropathic pain with zinc finger proteins |
WO2007014275A2 (fr) | 2005-07-26 | 2007-02-01 | Sangamo Biosciences, Inc. | Integration et expression ciblees de sequences d'acides nucleiques exogenes |
AU2007267887B2 (en) | 2006-05-25 | 2013-05-30 | Sangamo Therapeutics, Inc. | Variant Foki Cleavage Half-Domains |
PT2167523E (pt) | 2007-06-19 | 2014-09-22 | Univ Louisiana State | Síntese e utilização de análogos fosforotiolato antireversos do capuz de arn mensageiro |
EP2315829B1 (fr) | 2008-08-08 | 2015-02-11 | Mayo Foundation For Medical Education And Research | Cellules souches pluripotentes induites |
PT2534173T (pt) | 2010-02-08 | 2019-10-31 | Sangamo Therapeutics Inc | Semidomínios de clivagem manipulados |
CN104204225A (zh) | 2012-02-29 | 2014-12-10 | 桑格摩生物科学股份有限公司 | 治疗亨廷顿氏病的方法和组合物 |
DK3241902T3 (en) * | 2012-05-25 | 2018-05-07 | Univ California | METHODS AND COMPOSITIONS FOR RNA DIRECTIVE TARGET DNA MODIFICATION AND FOR RNA DIRECTIVE MODULATION OF TRANSCRIPTION |
EP3494997B1 (fr) | 2012-07-25 | 2019-09-18 | The Broad Institute, Inc. | Protéines de liaison à l'adn inductibles, outils de perturbation du génome et leurs applications |
US9181535B2 (en) | 2012-09-24 | 2015-11-10 | The Chinese University Of Hong Kong | Transcription activator-like effector nucleases (TALENs) |
DK2931897T3 (en) | 2012-12-12 | 2018-02-05 | Broad Inst Inc | CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
IL239344B1 (en) | 2012-12-12 | 2024-02-01 | Broad Inst Inc | Systems engineering, methods and optimal guiding components for sequence manipulation |
EP2931892B1 (fr) | 2012-12-12 | 2018-09-12 | The Broad Institute, Inc. | Procédés, modèles, systèmes et appareil pour identifier des séquences cibles pour les enzymes cas ou des systèmes crispr-cas pour des séquences cibles et transmettre les résultats associés |
IL300461A (en) | 2012-12-12 | 2023-04-01 | Harvard College | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
WO2014093701A1 (fr) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Génomique fonctionnelle employant des systèmes crispr-cas, des compositions, des procédés, des banques d'inactivation et leurs applications |
PL2931898T3 (pl) | 2012-12-12 | 2016-09-30 | Le Cong | Projektowanie i optymalizacja systemów, sposoby i kompozycje do manipulacji sekwencją z domenami funkcjonalnymi |
EP4234696A3 (fr) | 2012-12-12 | 2023-09-06 | The Broad Institute Inc. | Systèmes de composants crispr-cas, procédés et compositions pour la manipulation de séquence |
EP2784162B1 (fr) | 2012-12-12 | 2015-04-08 | The Broad Institute, Inc. | Ingénierie de systèmes, procédés et compositions de guidage optimisé pour manipulation de séquence |
US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
AU2014218621B2 (en) | 2013-02-25 | 2019-11-07 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
DK3527563T3 (da) * | 2013-03-12 | 2021-12-06 | Vertex Pharma | Dna-pk-inhibitorer |
US11332719B2 (en) | 2013-03-15 | 2022-05-17 | The Broad Institute, Inc. | Recombinant virus and preparations thereof |
US20160040155A1 (en) | 2013-04-16 | 2016-02-11 | University Of Washington Through Its Center For Commercialization | Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering |
EP3011034B1 (fr) | 2013-06-17 | 2019-08-07 | The Broad Institute, Inc. | Administration, utilisation et applications thérapeutiques de systèmes crispr-cas et compositions pour cibler les troubles et maladies en utilisant des éléments viraux |
KR20160030187A (ko) | 2013-06-17 | 2016-03-16 | 더 브로드 인스티튜트, 인코퍼레이티드 | 간의 표적화 및 치료를 위한 CRISPRCas 시스템, 벡터 및 조성물의 전달 및 용도 |
EP3011035B1 (fr) | 2013-06-17 | 2020-05-13 | The Broad Institute, Inc. | Test pour l'évaluation quantitative du clivage de sites cibles par une ou plusieurs séquences guides du système crispr-cas |
SG11201510327TA (en) | 2013-06-17 | 2016-01-28 | Broad Inst Inc | Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells |
WO2014204724A1 (fr) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Administration, modification et optimisation de systèmes guides tandems, méthodes et compositions pour la manipulation de séquence |
AU2014281027A1 (en) | 2013-06-17 | 2016-01-28 | Massachusetts Institute Of Technology | Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation |
EP3011033B1 (fr) | 2013-06-17 | 2020-02-19 | The Broad Institute, Inc. | Génomique fonctionnelle utilisant des systèmes crispr-cas, procédés de composition, cribles et applications de ces derniers |
KR101448678B1 (ko) | 2013-08-12 | 2014-10-08 | 김형기 | 단추 재봉실의 뿌리감기 장치 |
WO2015048556A1 (fr) | 2013-09-27 | 2015-04-02 | Stout Partners LP | Système et appareil de coordination et planification efficaces d'accès à des sites en ligne à débit limité pour obtenir des données destinées à être utilisées dans l'estimation de mesures sociales sur la base d'une évaluation adaptée au domaine d'exposition aux médias sociaux |
WO2015048577A2 (fr) | 2013-09-27 | 2015-04-02 | Editas Medicine, Inc. | Compositions et méthodes relatives aux répétitions palindromiques groupées, courtes et régulièrement espacées |
ES2780904T3 (es) | 2014-08-17 | 2020-08-27 | Broad Inst Inc | Edición genómica usando nickasas Cas9 |
KR20230070319A (ko) | 2014-11-21 | 2023-05-22 | 리제너론 파마슈티칼스 인코포레이티드 | 쌍 형성된 가이드 rna를 사용하는 표적화된 유전자 변형을 위한 방법 및 조성물 |
JP7033583B2 (ja) * | 2016-07-13 | 2022-03-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | ゲノム編集効率を高めるための方法、組成物及びキット |
US20200392540A1 (en) * | 2017-04-10 | 2020-12-17 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Compounds for Increasing Genome Editing Efficiency |
EP3388517A1 (fr) * | 2017-04-10 | 2018-10-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Composés pour accroître l'efficacité d'édition du génome |
-
2019
- 2019-01-16 IL IL276082A patent/IL276082B2/en unknown
- 2019-01-16 KR KR1020207023655A patent/KR20200109358A/ko not_active Application Discontinuation
- 2019-01-16 BR BR112020014140-2A patent/BR112020014140A2/pt unknown
- 2019-01-16 JP JP2020539231A patent/JP7466448B2/ja active Active
- 2019-01-16 US US16/962,441 patent/US20210060028A1/en active Pending
- 2019-01-16 MA MA051616A patent/MA51616A/fr unknown
- 2019-01-16 WO PCT/US2019/013783 patent/WO2019143675A1/fr unknown
- 2019-01-16 EA EA202091709A patent/EA202091709A1/ru unknown
- 2019-01-16 CN CN201980014489.9A patent/CN111741955B/zh active Active
- 2019-01-16 CA CA3088788A patent/CA3088788A1/fr active Pending
- 2019-01-16 AU AU2019209290A patent/AU2019209290B2/en active Active
- 2019-01-16 EP EP19703520.7A patent/EP3740479A1/fr active Pending
-
2023
- 2023-10-31 JP JP2023186635A patent/JP2023181402A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112020014140A2 (pt) | 2020-12-01 |
KR20200109358A (ko) | 2020-09-22 |
IL276082A (en) | 2020-08-31 |
EP3740479A1 (fr) | 2020-11-25 |
AU2019209290B2 (en) | 2024-03-07 |
EA202091709A1 (ru) | 2020-11-10 |
US20210060028A1 (en) | 2021-03-04 |
JP2023181402A (ja) | 2023-12-21 |
CN111741955B (zh) | 2024-02-23 |
JP2021511038A (ja) | 2021-05-06 |
CN111741955A (zh) | 2020-10-02 |
IL276082B1 (en) | 2023-09-01 |
CA3088788A1 (fr) | 2019-07-25 |
JP7466448B2 (ja) | 2024-04-12 |
AU2019209290A1 (en) | 2020-09-03 |
IL276082B2 (en) | 2024-01-01 |
WO2019143675A1 (fr) | 2019-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA51616A (fr) | Inhibiteurs d'adn-pk | |
MA54543A (fr) | Inhibiteurs de kif18a | |
MA54550A (fr) | Inhibiteurs de kif18a | |
DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
CL2021001078A1 (es) | 2-amino-n-heteroarilo-nicotinamidas como inhibidores de nav1.8. | |
MA52413A (fr) | Inhibiteurs de cd73 | |
MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
MA52812A (fr) | Inhibiteurs de sarm1 | |
MA52635A (fr) | Inhibiteurs de magl | |
MA53287A (fr) | Inhibiteurs de prmt5 | |
DK3681884T3 (da) | Rad51-inhibitorer | |
DK3571192T3 (da) | Jak1-selektive inhibitorer | |
DK3774817T3 (da) | Bcl6-hæmmere | |
MA55909A (fr) | Inhibiteurs de cdk | |
MA49006A (fr) | Inhibiteurs d'ip6k | |
CL2021000426A1 (es) | Inhibidores de la interacción proteína-proteína keap1-nrf2. | |
DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
DK3668955T3 (da) | Korrosionsinhibitor | |
DK3746446T3 (da) | PRC2-inhibitorer | |
MA46280A (fr) | Inhibiteurs de la dopamine-b-hydroxylase | |
DK3737403T3 (da) | Modificerede adenovira | |
DK3946179T3 (da) | Stomiposer | |
MA51611A (fr) | Inhibiteurs de pi4kiiibêta | |
MA52809A (fr) | Inhibiteurs de sarm1 |